Spis treści:
Spis załączników:
2024_Supervisory_Board_Report.pdf (REPORT)
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
2024_Supervisory_Board_Report.pdf (REPORT)
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 19 | / | 2025 | ||||||||
| Date of issue: | 2025-04-10 | ||||||||||
| Short name of the issuer | |||||||||||
| KRKA | |||||||||||
| Subject | |||||||||||
| 2024 Supervisory Board Report of Krka, d. d., Novo mesto | |||||||||||
| Official market - legal basis | |||||||||||
| art. 17. 1 MAR. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Based on the provisions of the Rules of the Ljubljana Stock Exchange, d. d., Ljubljana and Article 134 of the Market in Financial Instruments Act, Krka, d. d., Novo mesto publishes the 2024 Supervisory Board Report of Krka, d. d., Novo mesto. The report will be published on the Company's website (www.krka.biz) from 10 April 2025 onwards, for a period of at least 10 years. |
|||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| 2024 Supervisory Board Report.pdf2024 Supervisory Board Report.pdf | 2024 Supervisory Board Report | ||||||||||
| KRKA, TOVARNA ZDRAVIL D.D. | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| KRKA | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) |
||||||||||||
| 8501 | Nove Mesto | ||||||||||||
| (post code) | (city) | ||||||||||||
| Smarjeska | 6 | ||||||||||||
| (street) | (number) | ||||||||||||
| +386 7 331 21 11 | +386 7 332 15 37 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nie dotyczy | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2025-04-10 | Jože Colarič | President of the Management Board and CEO | |||
Źródło:Komunikaty spółek (ESPI)
